<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Module 7: Trauma, Bleeding & Surgical Emergencies</title>
    <style>
        /* EXACT STYLES FROM MODULE 6 */
        body {
            font-family: 'Calibri', 'Segoe UI', sans-serif;
            line-height: 1.5;
            color: #2c3e50;
            margin: 2cm;
            background-color: #ffffff;
            counter-reset: chapter section figure table;
        }
        
        h1 {
            font-size: 28pt;
            font-weight: bold;
            color: #1a5276;
            text-align: center;
            border-bottom: 3px double #3498db;
            padding-bottom: 10px;
            margin-bottom: 30px;
        }
        
        h2 {
            font-size: 18pt;
            font-weight: bold;
            color: #ffffff;
            background-color: #2980b9;
            padding: 10px 15px;
            border-radius: 5px;
            margin-top: 30px;
            page-break-after: avoid;
        }
        
        h3 {
            font-size: 14pt;
            font-weight: bold;
            color: #154360;
            margin-top: 20px;
            margin-bottom: 10px;
            page-break-after: avoid;
        }
        
        h4 {
            font-size: 12.5pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 15px;
            margin-bottom: 8px;
        }
        
        .module-title {
            font-size: 20pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 40px;
            border-left: 6px solid #3498db;
            padding-left: 15px;
        }
        
        .chapter-number {
            background-color: #3498db;
            color: white;
            padding: 5px 12px;
            border-radius: 50%;
            display: inline-block;
            margin-right: 10px;
            font-weight: bold;
        }
        
        /* Lists */
        ul, ol {
            padding-left: 1.5em;
            margin-bottom: 1em;
        }
        
        li {
            margin-bottom: 8px;
            font-size: 11.5pt;
        }
        
        .sub-list {
            list-style-type: lower-alpha;
            padding-left: 2.5em;
        }
        
        .drug-list {
            columns: 2;
            column-gap: 50px;
            margin-top: 15px;
        }
        
        .drug-list li {
            break-inside: avoid;
        }
        
        /* Special Boxes */
        .study-format {
            background-color: #e8f4fc;
            border: 1px solid #aed6f1;
            border-left: 6px solid #2e86c1;
            padding: 20px;
            margin-top: 30px;
            page-break-inside: avoid;
        }
        
        .clinical-pearl {
            background-color: #fff3cd;
            border: 1px solid #ffeaa7;
            border-left: 6px solid #fdcb6e;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .warning-box {
            background-color: #f8d7da;
            border: 1px solid #f5c6cb;
            border-left: 6px solid #e74c3c;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .definition-box {
            background-color: #d1ecf1;
            border: 1px solid #bee5eb;
            border-left: 6px solid #17a2b8;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        /* Tables */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 11pt;
        }
        
        .comparison-table th {
            background-color: #2980b9;
            color: white;
            padding: 10px;
            text-align: left;
            border: 1px solid #1a5276;
        }
        
        .comparison-table td {
            padding: 10px;
            border: 1px solid #ddd;
            vertical-align: top;
        }
        
        .comparison-table tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        /* Page Layout */
        .page-break {
            page-break-before: always;
        }
        
        .footer-note {
            font-size: 9pt;
            color: #7f8c8d;
            text-align: center;
            margin-top: 30px;
            border-top: 1px solid #ecf0f1;
            padding-top: 10px;
        }
        
        /* Drug Template - EXACT MATCH */
        .drug-template {
            background-color: #f9f9f9;
            border: 1px solid #ddd;
            padding: 20px;
            margin: 25px 0;
            border-radius: 5px;
            page-break-inside: avoid;
        }
        
        .drug-template h4 {
            color: #2c3e50;
            border-bottom: 2px solid #3498db;
            padding-bottom: 5px;
            margin-top: 0;
        }
        
        .template-section {
            margin-bottom: 15px;
        }
        
        .template-label {
            font-weight: bold;
            color: #2980b9;
            display: inline-block;
            width: 180px;
        }
        
        /* Emoji Styling */
        .emoji {
            font-size: 1.2em;
        }
        
        /* Print Specific */
        @media print {
            body {
                margin: 1.5cm;
                font-size: 11pt;
            }
            
            .page-break {
                page-break-before: always;
            }
            
            .no-print {
                display: none;
            }
            
            a {
                color: black;
                text-decoration: none;
            }
        }
        
        /* Learning Objectives */
        .learning-objectives {
            background-color: #e8f6f3;
            border: 1px solid #a2d9ce;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .objective-list {
            list-style-type: none;
            padding-left: 0;
        }
        
        .objective-list li:before {
            content: "‚úì ";
            color: #27ae60;
            font-weight: bold;
            margin-right: 10px;
        }
        
        /* Module 7 Specific Colors */
        .trauma-red {
            color: #e74c3c;
            font-weight: bold;
        }
        
        .bleeding-blue {
            color: #2980b9;
            font-weight: bold;
        }
        
        .analgesia-green {
            color: #27ae60;
            font-weight: bold;
        }
        
        .opioid-purple {
            color: #8e44ad;
            font-weight: bold;
        }
        
        .anti-inflammatory-orange {
            color: #e67e22;
            font-weight: bold;
        }
        
        .immunization-teal {
            color: #17a2b8;
            font-weight: bold;
        }
        
        /* Module 7 Specific Boxes */
        .trauma-box {
            background-color: #f2d7d5;
            border: 2px solid #c0392b;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .tranexamic-box {
            background-color: #d4e6f1;
            border: 2px solid #21618c;
            color: #1a5276;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .analgesia-box {
            background-color: #e8f8f5;
            border: 2px solid #45b39d;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .tetanus-box {
            background-color: #fef9e7;
            border: 2px solid #f1c40f;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .massive-transfusion-box {
            background-color: #2c3e50;
            border: 2px solid #34495e;
            color: white;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
        
        .procedure-box {
            background-color: #f4ecf7;
            border: 2px solid #8e44ad;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
    </style>
</head>
<body>

<div class="module-title">
    <span class="emoji">üü•</span> MODULE 7: TRAUMA, BLEEDING & SURGICAL EMERGENCIES (HIGH-YIELD)
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Tranexamic Acid, Vitamin K, Morphine, Fentanyl, Ketorolac, Tetanus Immunization)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master trauma resuscitation principles and massive transfusion protocols</li>
        <li>Understand TXA timing and dosing in trauma and major hemorrhage</li>
        <li>Learn acute pain management strategies in trauma and surgical emergencies</li>
        <li>Recognize and manage anticoagulation reversal scenarios</li>
        <li>Apply appropriate tetanus prophylaxis in wound management</li>
        <li>Understand opioid and NSAID selection based on patient factors</li>
        <li>Apply knowledge to ATLS protocols and trauma scenarios</li>
        <li>Manage perioperative emergencies and surgical complications</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: Trauma & Surgical Pharmacology</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è TRAUMA IS A RACE AGAINST TIME:</strong> The first hour is the "golden hour." TXA within 3 hours of injury. Tetanus within 24 hours of contaminated wounds. Pain control immediately. Know these timelines cold.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Trauma management follows three phases:<br>
    1. <strong class="trauma-red">Primary survey</strong> (ABCDEs: Airway, Breathing, Circulation, Disability, Exposure)<br>
    2. <strong class="trauma-red">Resuscitation</strong> (Fluids, blood products, medications to support physiology)<br>
    3. <strong class="trauma-red">Definitive care</strong> (Specific treatments for injuries, pain control, prevention)<br>
    This module focuses on the pharmacological interventions you MUST know.
</div>

<!-- STUDY FORMAT -->
<div class="study-format">
    <h3><span class="emoji">üìã</span> HOW WE WILL STUDY EACH DRUG (FIXED TEMPLATE)</h3>
    <p><strong>For every drug, we will follow ONE SAME FORMAT:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works at receptor/physiological level</li>
        <li><strong>Indications</strong> - Specific trauma/surgical scenarios</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact emergency dosing</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer safely</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious reactions and risks</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical wisdom</li>
    </ol>
</div>

<!-- CHAPTER 1: TRAUMA RESUSCITATION & MASSIVE TRANSFUSION -->
<h2><span class="chapter-number">1</span> Trauma Resuscitation & Massive Transfusion</h2>

<div class="definition-box">
    <strong>Damage Control Resuscitation (DCR):</strong> A strategy for major trauma involving permissive hypotension, haemostatic resuscitation, and damage control surgery to prevent the "lethal triad" of hypothermia, acidosis, and coagulopathy.
</div>

<h3>1.1 The Lethal Triad in Trauma</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Component</th>
            <th>Causes</th>
            <th>Effects</th>
            <th>Pharmacological Interventions</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Hypothermia</strong></td>
            <td>Exposure, cold fluids, impaired thermoregulation</td>
            <td>‚Ä¢ Coagulopathy (enzymes don't work)<br>‚Ä¢ Cardiac instability<br>‚Ä¢ Increased oxygen consumption</td>
            <td>‚Ä¢ Warm fluids/blood<br>‚Ä¢ Active warming devices<br>‚Ä¢ Minimize exposure</td>
        </tr>
        <tr>
            <td><strong>Acidosis</strong></td>
            <td>Hypoperfusion, anaerobic metabolism, shock</td>
            <td>‚Ä¢ Myocardial depression<br>‚Ä¢ Coagulopathy<br>‚Ä¢ Vasodilation</td>
            <td>‚Ä¢ Restore perfusion<br>‚Ä¢ Sodium bicarbonate (limited role)<br>‚Ä¢ Avoid excessive saline</td>
        </tr>
        <tr>
            <td><strong>Coagulopathy</strong></td>
            <td>Dilution, consumption, fibrinolysis, platelet dysfunction</td>
            <td>‚Ä¢ Ongoing hemorrhage<br>‚Ä¢ Multi-organ failure<br>‚Ä¢ Death</td>
            <td>‚Ä¢ TXA<br>‚Ä¢ Blood products (FFP, platelets, cryo)<br>‚Ä¢ Vitamin K (for warfarin)</td>
        </tr>
    </tbody>
</table>

<h3>1.2 Massive Transfusion Protocol (MTP)</h3>

<div class="massive-transfusion-box">
    <strong>ü©∏ MASSIVE TRANSFUSION PROTOCOL (1:1:1 RATIO):</strong><br>
    ‚Ä¢ <strong>Definition:</strong> >10 units PRBCs in 24h OR >4 units in 1h OR replacement of entire blood volume<br>
    ‚Ä¢ <strong>Ratio:</strong> 1 unit PRBCs : 1 unit FFP : 1 unit platelets (or 1 pack = 6 pooled units)<br>
    ‚Ä¢ <strong>Additions:</strong> Cryoprecipitate/fibrinogen concentrate, calcium, TXA<br>
    ‚Ä¢ <strong>Monitoring:</strong> TEG/ROTEM if available, labs q30-60min (Hb, PT/INR, fibrinogen, Ca¬≤‚Å∫)<br>
    <br>
    <strong>CRYSTALLOID RESTRICTION:</strong><br>
    ‚Ä¢ Limit to 1-2L initially, then switch to blood products<br>
    ‚Ä¢ Avoid excessive saline (dilutional coagulopathy, hyperchloremic acidosis)<br>
    ‚Ä¢ Use balanced solutions (PlasmaLyte, Hartmann's) if available
</div>

<!-- CHAPTER 2: DRUG 1 - TRANEXAMIC ACID (TXA) -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Tranexamic Acid (TXA)</h2>

<div class="drug-template">
    <h4>TRANEXAMIC ACID (TXA) - ANTIFIBRINOLYTIC FOR TRAUMA & HEMORRHAGE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Synthetic lysine analogue, antifibrinolytic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Competitively inhibits plasminogen activation to plasmin<br>
        ‚Ä¢ At higher doses, non-competitively inhibits plasmin<br>
        ‚Ä¢ Reduces breakdown of fibrin clots ‚Üí stabilizes clot formation<br>
        ‚Ä¢ Reduces bleeding without increasing thrombotic risk at trauma doses<br>
        ‚Ä¢ Also has anti-inflammatory properties (reduces complement activation)<br>
        ‚Ä¢ Minimal effect on coagulation parameters (PT/INR, aPTT)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Trauma with significant hemorrhage or risk of significant hemorrhage<br>
        ‚Ä¢ Post-partum hemorrhage (obstetric emergencies)<br>
        ‚Ä¢ Major surgical bleeding (cardiac, orthopaedic, spinal surgery)<br>
        ‚Ä¢ Hereditary angioedema (prophylaxis and treatment)<br>
        ‚Ä¢ Menorrhagia (oral formulation)<br>
        ‚Ä¢ Upper GI bleeding (emerging evidence)<br>
        ‚Ä¢ Epistaxis refractory to packing
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Active thrombosis (DVT, PE, stroke within 30 days)<br>
        ‚Ä¢ Known hypersensitivity to tranexamic acid<br>
        ‚Ä¢ Subarachnoid hemorrhage (increased risk of cerebral ischemia)<br>
        ‚Ä¢ Color vision disturbances (rare side effect, avoid if history)<br>
        ‚Ä¢ Severe renal impairment (CrCl <30 mL/min) - requires dose reduction<br>
        ‚Ä¢ Concurrent use of factor IX complex or anti-inhibitor coagulant complex
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="bleeding-blue">Trauma hemorrhage (CRASH-2 protocol):</strong> 1 g IV over 10 min, then 1 g IV over 8 hours<br>
        ‚Ä¢ <strong class="bleeding-blue">Massive hemorrhage:</strong> 1 g IV bolus, consider additional 1 g after 1 hour if ongoing bleed<br>
        ‚Ä¢ <strong class="bleeding-blue">Surgical bleeding:</strong> 10-20 mg/kg IV pre-incision, then 1 mg/kg/hr infusion<br>
        ‚Ä¢ <strong class="bleeding-blue">Post-partum hemorrhage:</strong> 1 g IV over 10 min, may repeat after 30 min if needed<br>
        ‚Ä¢ <strong class="bleeding-blue">Oral (menorrhagia):</strong> 1-1.5 g TID-QID during menses<br>
        ‚Ä¢ <strong class="bleeding-blue">Max daily dose:</strong> 4-6 g (trauma/surgical), 4 g (other indications)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="bleeding-blue">Trauma/surgical:</strong> 15 mg/kg IV load, then 2 mg/kg/hr infusion<br>
        ‚Ä¢ <strong class="bleeding-blue">Alternative:</strong> 10 mg/kg IV q6-8h<br>
        ‚Ä¢ <strong class="bleeding-blue">Neonates/infants:</strong> Limited data - 10 mg/kg IV over 10 min<br>
        ‚Ä¢ <strong class="bleeding-blue">Cardiac surgery:</strong> Load 30 mg/kg, then 16 mg/kg/hr, then 2 mg/kg/hr<br>
        ‚Ä¢ <strong class="bleeding-blue">Max pediatric dose:</strong> Adult dosing if weight >50 kg
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="bleeding-blue">Routes:</strong> IV (preferred in emergencies), oral, topical<br>
        ‚Ä¢ <strong class="bleeding-blue">Preparation:</strong> 100 mg/mL (10 mL = 1 g), 500 mg/5 mL vials<br>
        ‚Ä¢ <strong class="bleeding-blue">For IV bolus:</strong> Give undiluted over 10 minutes (at least)<br>
        ‚Ä¢ <strong class="bleeding-blue">For infusion:</strong> Dilute in 50-100 mL NS or D5W, infuse over 8 hours<br>
        ‚Ä¢ <strong class="bleeding-blue">Compatibility:</strong> Compatible with most IV solutions, NOT with penicillin, blood products<br>
        ‚Ä¢ <strong class="bleeding-blue">Oral:</strong> 500 mg tablets, crush and give via NG if needed
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nausea, vomiting, diarrhea (especially oral)<br>
        ‚Ä¢ Headache, dizziness<br>
        ‚Ä¢ Visual disturbances (rare, reversible)<br>
        ‚Ä¢ Hypotension with rapid IV administration<br>
        ‚Ä¢ Injection site reactions<br>
        ‚Ä¢ Fatigue, malaise
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Thromboembolic events (DVT, PE, stroke) - risk increases with higher doses/longer use<br>
        ‚Ä¢ Seizures (especially with high doses in cardiac surgery patients)<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Color vision abnormalities, retinal changes<br>
        ‚Ä¢ Acute renal cortical necrosis (rare, with ureteral obstruction)<br>
        ‚Ä¢ Intracranial thrombosis (avoid in subarachnoid hemorrhage)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="bleeding-blue">Anticoagulants/antiplatelets:</strong> May reduce effectiveness of TXA<br>
        ‚Ä¢ <strong class="bleeding-blue">Factor IX complex:</strong> Increased thrombosis risk - contraindicated<br>
        ‚Ä¢ <strong class="bleeding-blue">Ticlopidine:</strong> Increased thrombosis risk<br>
        ‚Ä¢ <strong class="bleeding-blue">Hormonal contraceptives:</strong> Increased thrombosis risk (theoretical)<br>
        ‚Ä¢ <strong class="bleeding-blue">Tissue plasminogen activators (tPA):</strong> Antagonizes effect
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="bleeding-blue">"3 HOUR RULE":</strong> Give within 3 hours of injury - mortality benefit up to 3h, harmful after?<br>
        ‚Ä¢ <strong class="bleeding-blue">CRASH-2 trial:</strong> 1g load + 1g over 8h reduced mortality 1.5% (NNT=67)<br>
        ‚Ä¢ <strong class="bleeding-blue">MATTERs study:</strong> Combat trauma with MTP - 6.5% absolute mortality reduction<br>
        ‚Ä¢ <strong class="bleeding-blue">SBP <90 or HR >110:</strong> Clinical signs of significant hemorrhage - give TXA<br>
        ‚Ä¢ <strong class="bleeding-blue">Not for minor bleeding:</strong> Use only when significant hemorrhage suspected<br>
        ‚Ä¢ <strong class="bleeding-blue">Avoid in head injury alone:</strong> CRASH-3 showed benefit only if GCS >8 or no significant ICH<br>
        ‚Ä¢ <strong class="bleeding-blue">Cost-effective:</strong> ~$5 per treatment - one of most cost-effective interventions<br>
        ‚Ä¢ <strong class="bleeding-blue">Pre-hospital use:</strong> Safe and effective when given by paramedics
    </div>
</div>

<div class="tranexamic-box">
    <strong>ü©∏ TXA IN TRAUMA - CRITICAL TIMING:</strong><br>
    ‚Ä¢ <strong>WITHIN 1 HOUR:</strong> Maximum benefit (32% mortality reduction)<br>
    ‚Ä¢ <strong>1-3 HOURS:</strong> Still beneficial (mortality reduction)<br>
    ‚Ä¢ <strong>>3 HOURS:</strong> May be harmful (increased mortality in CRASH-2)<br>
    ‚Ä¢ <strong>DOSING:</strong> 1g IV over 10 min + 1g over 8 hours<br>
    ‚Ä¢ <strong>WHEN:</strong> SBP <90 OR HR >110 OR significant hemorrhage suspected
</div>

<!-- CHAPTER 3: DRUG 2 - VITAMIN K (INJECTABLE) -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Vitamin K (Injectable)</h2>

<div class="drug-template">
    <h4>VITAMIN K (PHYTOMENADIONE) - ANTICOAGULATION REVERSAL</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Fat-soluble vitamin, cofactor for clotting factors
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Essential cofactor for Œ≥-glutamyl carboxylase enzyme<br>
        ‚Ä¢ Converts inactive clotting factors II, VII, IX, X to active forms<br>
        ‚Ä¢ Also activates proteins C, S, and Z (natural anticoagulants)<br>
        ‚Ä¢ Does NOT reverse heparin or direct oral anticoagulants (DOACs)<br>
        ‚Ä¢ IV form works within hours, oral takes 24+ hours<br>
        ‚Ä¢ Fat-soluble - requires bile salts for oral absorption
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Warfarin/coumarin overdose or excessive anticoagulation<br>
        ‚Ä¢ Reversal of vitamin K antagonists before urgent surgery/procedures<br>
        ‚Ä¢ Vitamin K deficiency bleeding (VKDB) in neonates<br>
        ‚Ä¢ Malabsorption syndromes (IBD, cystic fibrosis, short bowel)<br>
        ‚Ä¢ Antibiotic-associated hypoprothrombinemia<br>
        ‚Ä¢ Liver disease with prolonged INR (partial correction)<br>
        ‚Ä¢ Rodenticide poisoning (superwarfarin exposure)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to vitamin K preparations<br>
        ‚Ä¢ Severe hepatic failure (may not respond)<br>
        ‚Ä¢ Not for heparin reversal (use protamine)<br>
        ‚Ä¢ Not for DOAC reversal (use specific antidotes)<br>
        ‚Ä¢ Relative: Recent thrombotic event (risk of thrombosis with reversal)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="bleeding-blue">Warfarin reversal (no bleeding):</strong> 1-2.5 mg PO, repeat in 24h if needed<br>
        ‚Ä¢ <strong class="bleeding-blue">Warfarin reversal (minor bleeding):</strong> 2.5-5 mg PO, may repeat in 24h<br>
        ‚Ä¢ <strong class="bleeding-blue">Warfarin reversal (major bleeding):</strong> 5-10 mg IV slow + 4-factor PCC<br>
        ‚Ä¢ <strong class="bleeding-blue">INR >10 no bleeding:</strong> 2.5-5 mg PO, repeat as needed<br>
        ‚Ä¢ <strong class="bleeding-blue">Pre-procedure:</strong> 1-2.5 mg PO for 3 days prior, check INR day of<br>
        ‚Ä¢ <strong class="bleeding-blue">Rodenticide poisoning:</strong> 10-25 mg PO daily for weeks to months
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="bleeding-blue">Neonatal VKDB prophylaxis:</strong> 0.5-1 mg IM at birth (single dose)<br>
        ‚Ä¢ <strong class="bleeding-blue">Neonatal VKDB treatment:</strong> 1-2 mg IV (severe cases may need FFP)<br>
        ‚Ä¢ <strong class="bleeding-blue">Warfarin reversal:</strong> 0.025-0.1 mg/kg IV/PO<br>
        ‚Ä¢ <strong class="bleeding-blue">Vitamin K deficiency:</strong> 1-2 mg IM/SC weekly, or 2.5-5 mg PO twice weekly<br>
        ‚Ä¢ <strong class="bleeding-blue">Cystic fibrosis/malabsorption:</strong> 2.5-5 mg PO daily or 1-2 mg IM weekly
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="bleeding-blue">Routes:</strong> IV (slow infusion), IM, SC, PO<br>
        ‚Ä¢ <strong class="bleeding-blue">Preparation:</strong> 1 mg/mL (1 mL ampoules), 10 mg/mL (multidose vials)<br>
        ‚Ä¢ <strong class="bleeding-blue">For IV:</strong> MUST dilute and give slowly - 1 mg/min max rate<br>
        ‚Ä¢ <strong class="bleeding-blue">Dilution:</strong> Mix with 50 mL NS or D5W, infuse over 20-60 minutes<br>
        ‚Ä¢ <strong class="bleeding-blue">IM/SC:</strong> Preferred over IV when possible (less anaphylactoid risk)<br>
        ‚Ä¢ <strong class="bleeding-blue">Oral:</strong> 5 mg tablets, liquid formulations available
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Flushing, dizziness (especially with rapid IV)<br>
        ‚Ä¢ Altered taste (with IV administration)<br>
        ‚Ä¢ Pain/swelling at injection site (IM/SC)<br>
        ‚Ä¢ Hyperbilirubinemia in neonates (especially with high doses)<br>
        ‚Ä¢ Skin reactions (rash, urticaria)<br>
        ‚Ä¢ Gastrointestinal upset (oral)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylactoid reactions (with rapid IV administration)<br>
        ‚Ä¢ Death (rare, with rapid IV undiluted)<br>
        ‚Ä¢ Hyperbilirubinemia/kernicterus in neonates<br>
        ‚Ä¢ Thrombosis (with rapid reversal of anticoagulation)<br>
        ‚Ä¢ Hemolytic anemia in G6PD deficiency (theoretical)<br>
        ‚Ä¢ "Purple glove syndrome" - skin discoloration at injection site
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="bleeding-blue">Warfarin:</strong> Antagonizes effect (obvious)<br>
        ‚Ä¢ <strong class="bleeding-blue">Antibiotics:</strong> Broad-spectrum abx reduce vitamin K production by gut flora<br>
        ‚Ä¢ <strong class="bleeding-blue">Orlistat, cholestyramine:</strong> Reduce absorption of oral vitamin K<br>
        ‚Ä¢ <strong class="bleeding-blue">Phenytoin, barbiturates:</strong> Increase metabolism via CYP induction<br>
        ‚Ä¢ <strong class="bleeding-blue">Vitamin E:</strong> High doses may antagonize vitamin K
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="bleeding-blue">"IV = Slow or No":</strong> Never give IV push - dilute and infuse over 20-60 min<br>
        ‚Ä¢ <strong class="bleeding-blue">Major bleeding + warfarin:</strong> Give 4-factor PCC (immediate) + Vitamin K 5-10 mg IV (sustained)<br>
        ‚Ä¢ <strong class="bleeding-blue">Onset of action:</strong> IV: 1-2 hours, PO: 6-12 hours, full effect 24-48 hours<br>
        ‚Ä¢ <strong class="bleeding-blue">Duration:</strong> Single dose lasts 2-5 days depending on liver function<br>
        ‚Ä¢ <strong class="bleeding-blue">Liver disease:</strong> May have partial response - often need FFP as well<br>
        ‚Ä¢ <strong class="bleeding-blue">Resistance:</strong> Superwarfarins (rodenticides) may need months of treatment<br>
        ‚Ä¢ <strong class="bleeding-blue">Neonates:</strong> IM vitamin K at birth prevents hemorrhagic disease (standard care)<br>
        ‚Ä¢ <strong class="bleeding-blue">Antidote for vitamin K antagonists ONLY</strong> - not heparin, not DOACs
    </div>
</div>

<!-- CHAPTER 4: DRUG 3 - MORPHINE -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Morphine</h2>

<div class="drug-template">
    <h4>MORPHINE - GOLD STANDARD OPIOID FOR MODERATE-SEVERE PAIN</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Natural opium alkaloid, mu-opioid receptor agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Primarily agonizes mu-opioid receptors in CNS and periphery<br>
        ‚Ä¢ Also has delta and kappa opioid receptor activity<br>
        ‚Ä¢ Inhibits pain transmission in dorsal horn of spinal cord<br>
        ‚Ä¢ Activates descending inhibitory pathways from brainstem<br>
        ‚Ä¢ Alters emotional response to pain (limbic system)<br>
        ‚Ä¢ Causes peripheral vasodilation (histamine release)<br>
        ‚Ä¢ Metabolized to active metabolites (M6G - more potent, M3G - neuroexcitatory)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Moderate to severe acute pain (trauma, post-op, MI, sickle cell crisis)<br>
        ‚Ä¢ Chronic cancer pain (oral formulations)<br>
        ‚Ä¢ Dyspnea in palliative care (reduces air hunger)<br>
        ‚Ä¢ Sedation in mechanically ventilated patients (ICU)<br>
        ‚Ä¢ Pre-medication before anesthesia<br>
        ‚Ä¢ Acute pulmonary edema (reduces preload and anxiety)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to morphine or opioids<br>
        ‚Ä¢ Acute or severe asthma/COPD (risk of respiratory depression)<br>
        ‚Ä¢ Paralytic ileus, GI obstruction<br>
        ‚Ä¢ Increased intracranial pressure (risk of hypercapnia ‚Üí increased ICP)<br>
        ‚Ä¢ Severe hepatic impairment (accumulation of metabolites)<br>
        ‚Ä¢ Concurrent MAOI use or within 14 days (risk of serotonin syndrome)<br>
        ‚Ä¢ Acute pancreatitis (may cause spasm of sphincter of Oddi)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="opioid-purple">IV acute pain:</strong> 2-5 mg IV q5-15min titrated to pain relief<br>
        ‚Ä¢ <strong class="opioid-purple">IV infusion:</strong> 1-5 mg/hr after loading dose, titrate to effect<br>
        ‚Ä¢ <strong class="opioid-purple">IM/SC:</strong> 5-15 mg q4h (less preferred due to variable absorption)<br>
        ‚Ä¢ <strong class="opioid-purple">MI/pulmonary edema:</strong> 2-4 mg IV, repeat q5-15min<br>
        ‚Ä¢ <strong class="opioid-purple">Oral immediate-release:</strong> 10-30 mg q4h<br>
        ‚Ä¢ <strong class="opioid-purple">Oral controlled-release:</strong> Not for acute pain initiation
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="opioid-purple">IV/IM/SC:</strong> 0.05-0.1 mg/kg q2-4h (max initial dose 4-5 mg)<br>
        ‚Ä¢ <strong class="opioid-purple">IV infusion:</strong> 0.01-0.04 mg/kg/hr after loading dose<br>
        ‚Ä¢ <strong class="opioid-purple">Oral:</strong> 0.2-0.5 mg/kg q4-6h<br>
        ‚Ä¢ <strong class="opioid-purple">Neonates:</strong> 0.05 mg/kg IV/IM q4-8h (prolonged half-life)<br>
        ‚Ä¢ <strong class="opioid-purple">PCA (patient-controlled analgesia):</strong> 0.01-0.02 mg/kg q6-10min + background
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="opioid-purple">Routes:</strong> IV (preferred in emergencies), IM, SC, PO, PR, epidural, intrathecal<br>
        ‚Ä¢ <strong class="opioid-purple">Preparation:</strong> 1 mg/mL, 2 mg/mL, 4 mg/mL, 5 mg/mL, 10 mg/mL, 15 mg/mL<br>
        ‚Ä¢ <strong class="opioid-purple">For IV push:</strong> Dilute to at least 1 mg/mL, give over 4-5 minutes<br>
        ‚Ä¢ <strong class="opioid-purple">For infusion:</strong> Typical concentration 1 mg/mL in NS or D5W<br>
        ‚Ä¢ <strong class="opioid-purple">Compatibility:</strong> Compatible with most solutions, NOT with alkaline solutions (precipitate)<br>
        ‚Ä¢ <strong class="opioid-purple">Stability:</strong> 24 hours at room temperature when diluted
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Sedation, drowsiness, confusion (especially elderly)<br>
        ‚Ä¢ Nausea, vomiting (30% of patients)<br>
        ‚Ä¢ Constipation (almost universal with chronic use)<br>
        ‚Ä¢ Pruritus (especially facial, not allergy - histamine release)<br>
        ‚Ä¢ Urinary retention<br>
        ‚Ä¢ Dry mouth, sweating<br>
        ‚Ä¢ Miosis (pinpoint pupils - pathognomonic but tolerance develops)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Respiratory depression (dose-related, watch for <8 breaths/min)<br>
        ‚Ä¢ Hypotension (especially with hypovolemia or rapid administration)<br>
        ‚Ä¢ Severe bronchospasm (histamine release in susceptible)<br>
        ‚Ä¢ Seizures (with high doses or accumulation of M3G metabolite in renal failure)<br>
        ‚Ä¢ Hyperalgesia (with chronic high-dose use)<br>
        ‚Ä¢ Adrenal insufficiency (chronic use)<br>
        ‚Ä¢ Serotonin syndrome (especially with other serotonergic drugs)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="opioid-purple">Other CNS depressants:</strong> Synergistic respiratory depression (benzos, alcohol, barbiturates)<br>
        ‚Ä¢ <strong class="opioid-purple">MAOIs:</strong> Serotonin syndrome risk - contraindicated<br>
        ‚Ä¢ <strong class="opioid-purple">SSRIs, SNRIs, TCAs:</strong> Increased serotonin syndrome risk<br>
        ‚Ä¢ <strong class="opioid-purple">Anticholinergics:</strong> Increased constipation/urinary retention risk<br>
        ‚Ä¢ <strong class="opioid-purple">Mixed agonist-antagonists (pentazocine):</strong> Precipitate withdrawal<br>
        ‚Ä¢ <strong class="opioid-purple">Protease inhibitors (ritonavir):</strong> Increased morphine levels
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="opioid-purple">"Start low, go slow"</strong> especially in opioid-na√Øve, elderly, renal impairment<br>
        ‚Ä¢ <strong class="opioid-purple">Renal failure warning:</strong> Metabolites accumulate ‚Üí neuroexcitation, seizures, myoclonus<br>
        ‚Ä¢ <strong class="opioid-purple">Histamine release:</strong> Causes flushing, itching, hypotension - NOT anaphylaxis<br>
        ‚Ä¢ <strong class="opioid-purple">Equianalgesic:</strong> 10 mg IV morphine = 30 mg PO morphine (3:1 ratio)<br>
        ‚Ä¢ <strong class="opioid-purple">Naloxone ready:</strong> Have reversal agent available (0.4 mg/mL)<br>
        ‚Ä¢ <strong class="opioid-purple">Pain is the 5th vital sign:</strong> Assess before and after administration (0-10 scale)<br>
        ‚Ä¢ <strong class="opioid-purple">MI pain:</strong> Morphine reduces anxiety, preload, oxygen demand - still first line<br>
        ‚Ä¢ <strong class="opioid-purple">PCA:</strong> Patient-controlled analgesia gives better pain control with less total dose
    </div>
</div>

<!-- CHAPTER 5: DRUG 4 - FENTANYL -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Fentanyl</h2>

<div class="drug-template">
    <h4>FENTANYL - POTENT, RAPID-ONSET SYNTHETIC OPIOID</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Synthetic phenylpiperidine, mu-opioid receptor agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Highly selective mu-opioid receptor agonist (100x more potent than morphine)<br>
        ‚Ä¢ Lipid soluble - rapid CNS penetration (onset 1-2 minutes IV)<br>
        ‚Ä¢ Minimal histamine release ‚Üí less hypotension than morphine<br>
        ‚Ä¢ Short context-sensitive half-time (accumulates less with infusion)<br>
        ‚Ä¢ Metabolized by CYP3A4 to inactive metabolites (mostly)<br>
        ‚Ä¢ Transdermal and transmucosal formulations have different pharmacokinetics
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Severe acute pain (trauma, burns, post-op)<br>
        ‚Ä¢ Procedural sedation and analgesia (PSA)<br>
        ‚Ä¢ Rapid sequence intubation analgesia component<br>
        ‚Ä¢ Chronic cancer pain (transdermal patches)<br>
        ‚Ä¢ Breakthrough cancer pain (oral transmucosal)<br>
        ‚Ä¢ Pre-medication before painful procedures<br>
        ‚Ä¢ Cardiac surgery/ICU analgesia (hemodynamically stable)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to fentanyl<br>
        ‚Ä¢ Opioid-na√Øve patients for transdermal use (high overdose risk)<br>
        ‚Ä¢ Acute or severe asthma/COPD (risk of respiratory depression)<br>
        ‚Ä¢ Paralytic ileus<br>
        ‚Ä¢ Increased intracranial pressure (risk of hypercapnia)<br>
        ‚Ä¢ Hepatic impairment (may prolong effect)<br>
        ‚Ä¢ MAOI use within 14 days
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="opioid-purple">IV analgesia:</strong> 25-100 mcg (0.025-0.1 mg) q5-10min titrated<br>
        ‚Ä¢ <strong class="opioid-purple">IV infusion:</strong> 25-100 mcg/hr after loading dose<br>
        ‚Ä¢ <strong class="opioid-purple">PSA/procedural:</strong> 50-100 mcg IV with midazolam 1-2 mg<br>
        ‚Ä¢ <strong class="opioid-purple">RSI analgesia:</strong> 1-3 mcg/kg IV (typically 100-300 mcg)<br>
        ‚Ä¢ <strong class="opioid-purple">Transdermal:</strong> 12-100 mcg/hr patch q72h (chronic pain only)<br>
        ‚Ä¢ <strong class="opioid-purple">Oral transmucosal:</strong> 200-400 mcg for breakthrough cancer pain
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="opioid-purple">IV analgesia:</strong> 0.5-1 mcg/kg q30-60min (max 50 mcg/dose)<br>
        ‚Ä¢ <strong class="opioid-purple">IV infusion:</strong> 0.5-2 mcg/kg/hr after loading dose<br>
        ‚Ä¢ <strong class="opioid-purple">PSA:</strong> 1-2 mcg/kg IV with midazolam 0.05 mg/kg<br>
        ‚Ä¢ <strong class="opioid-purple">Neonates:</strong> 0.5-3 mcg/kg IV q2-4h (prolonged half-life)<br>
        ‚Ä¢ <strong class="opioid-purple">Transdermal:</strong> Not recommended <12 years<br>
        ‚Ä¢ <strong class="opioid-purple">PCA:</strong> 0.25-0.5 mcg/kg q6-10min
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="opioid-purple">Routes:</strong> IV, IM, transdermal, transmucosal, intranasal, epidural<br>
        ‚Ä¢ <strong class="opioid-purple">Preparation:</strong> 50 mcg/mL (most common), 100 mcg/mL<br>
        ‚Ä¢ <strong class="opioid-purple">For IV push:</strong> Give undiluted over 1-2 minutes<br>
        ‚Ä¢ <strong class="opioid-purple">For infusion:</strong> Typical concentration 10-40 mcg/mL in NS or D5W<br>
        ‚Ä¢ <strong class="opioid-purple">Transdermal:</strong> 12, 25, 50, 75, 100 mcg/hr patches (apply to chest/back/upper arm)<br>
        ‚Ä¢ <strong class="opioid-purple">Compatibility:</strong> Compatible with most solutions, incompatible with barbiturates
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Respiratory depression (dose-related)<br>
        ‚Ä¢ Sedation, dizziness<br>
        ‚Ä¢ Nausea, vomiting (less than morphine)<br>
        ‚Ä¢ Constipation (with chronic use)<br>
        ‚Ä¢ Pruritus (less histamine release than morphine)<br>
        ‚Ä¢ Muscle rigidity (especially with high rapid doses - "wooden chest")<br>
        ‚Ä¢ Bradycardia (opioid receptor effect)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Severe respiratory depression/apnea<br>
        ‚Ä¢ Chest wall rigidity (treat with naloxone or neuromuscular blockade)<br>
        ‚Ä¢ Hypotension (less than morphine)<br>
        ‚Ä¢ Serotonin syndrome (with other serotonergic drugs)<br>
        ‚Ä¢ Transdermal overdose (heat increases absorption, delayed onset/offset)<br>
        ‚Ä¢ Withdrawal symptoms if stopped abruptly (chronic use)<br>
        ‚Ä¢ Adrenal insufficiency (chronic use)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="opioid-purple">CYP3A4 inhibitors:</strong> Increased levels (ketoconazole, ritonavir, erythromycin)<br>
        ‚Ä¢ <strong class="opioid-purple">CYP3A4 inducers:</strong> Decreased levels (rifampin, carbamazepine, phenytoin)<br>
        ‚Ä¢ <strong class="opioid-purple">Other CNS depressants:</strong> Synergistic effects (benzos, alcohol, barbiturates)<br>
        ‚Ä¢ <strong class="opioid-purple">MAOIs:</strong> Contraindicated - serotonin syndrome risk<br>
        ‚Ä¢ <strong class="opioid-purple">Neuromuscular blockers:</strong> Potentiation of muscle relaxation
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="opioid-purple">"Mcg not mg!"</strong> 100x more potent than morphine - dosing errors can be fatal<br>
        ‚Ä¢ <strong class="opioid-purple">Onset:</strong> 1-2 minutes IV, peak 3-5 minutes, duration 30-60 minutes<br>
        ‚Ä¢ <strong class="opioid-purple">Wooden chest syndrome:</strong> High rapid doses cause chest wall rigidity - treat with naloxone 0.4 mg or suxamethonium<br>
        ‚Ä¢ <strong class="opioid-purple">Transdermal patches:</strong> Heat (fever, heating pads) increases absorption 3x - overdose risk<br>
        ‚Ä¢ <strong class="opioid-purple">Equianalgesic:</strong> 100 mcg IV fentanyl ‚âà 10 mg IV morphine ‚âà 1 mg IV hydromorphone<br>
        ‚Ä¢ <strong class="opioid-purple">PSA with midazolam:</strong> Classic combination - fentanyl for pain, midazolam for amnesia/anxiety<br>
        ‚Ä¢ <strong class="opioid-purple">Street fentanyl:</strong> Illicit fentanyl is 50-100x more potent than heroin - tiny amounts fatal<br>
        ‚Ä¢ <strong class="opioid-purple">Naloxone:</strong> May need higher doses for fentanyl overdose (2-10 mg sometimes needed)
    </div>
</div>

<!-- CHAPTER 6: DRUG 5 - KETOROLAC -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Ketorolac</h2>

<div class="drug-template">
    <h4>KETOROLAC - POTENT PARENTERAL NSAID FOR ACUTE PAIN</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Non-steroidal anti-inflammatory drug (NSAID), pyrrolizine carboxylic acid derivative
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Reversible inhibition of cyclooxygenase (COX-1 and COX-2) enzymes<br>
        ‚Ä¢ Reduces prostaglandin synthesis ‚Üí decreased inflammation, pain, fever<br>
        ‚Ä¢ Peripheral and central analgesic effects<br>
        ‚Ä¢ No effect on opioid receptors ‚Üí no respiratory depression<br>
        ‚Ä¢ Antiplatelet effect (reversible, lasts 24-48 hours after dose)<br>
        ‚Ä¢ No development of tolerance or physical dependence
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Short-term management (‚â§5 days) of moderate to severe acute pain<br>
        ‚Ä¢ Post-operative pain (often used as opioid-sparing agent)<br>
        ‚Ä¢ Renal colic (particularly effective for ureteric stone pain)<br>
        ‚Ä¢ Musculoskeletal trauma (fractures, sprains, soft tissue injury)<br>
        ‚Ä¢ Migraine headache (IV/IM route)<br>
        ‚Ä¢ Alternative to opioids when respiratory depression concern<br>
        ‚Ä¢ Dental pain (oral formulation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Active or history of peptic ulcer disease/GI bleeding<br>
        ‚Ä¢ Advanced renal disease (CrCl <30 mL/min) or volume depletion<br>
        ‚Ä¢ History of asthma, urticaria, or allergic reaction to NSAIDs/ASA<br>
        ‚Ä¢ Peri-operative pain in CABG surgery (increased CV/thrombotic events)<br>
        ‚Ä¢ Pregnancy (especially 3rd trimester - premature ductus closure)<br>
        ‚Ä¢ Hemorrhagic diathesis or coagulopathy<br>
        ‚Ä¢ Concurrent use of other NSAIDs or anticoagulants<br>
        ‚Ä¢ Age ‚â•65 years (relative - increased risk of adverse effects)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IV/IM loading dose:</strong> 15-30 mg (30 mg for patients <50 kg only if benefits > risks)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IV/IM maintenance:</strong> 15-30 mg q6h (max 60 mg first day, then max 120 mg/day)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Oral:</strong> 10 mg q4-6h (max 40 mg/day) after parenteral therapy<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Renal colic:</strong> 30 mg IV single dose often sufficient<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">MAXIMUM DURATION:</strong> 5 days total (IV/IM + PO combined)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Elderly (‚â•65 years):</strong> Reduce dose by 50% (7.5-15 mg q6h)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IV (‚â•2 years):</strong> 0.5 mg/kg (max 15 mg) q6h<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IM (‚â•2 years):</strong> 1 mg/kg (max 30 mg) single dose, then 0.5 mg/kg q6h<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Oral (‚â•2 years):</strong> 0.25 mg/kg q6-8h after parenteral therapy<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Maximum duration:</strong> 5 days total<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Neonates/infants <2 years:</strong> Not recommended
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Routes:</strong> IV (preferred), IM, PO<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Preparation:</strong> 15 mg/mL (1 mL), 30 mg/mL (1 mL, 2 mL)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">For IV push:</strong> Give undiluted over at least 15 seconds<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">For IV infusion:</strong> Can dilute in 50-100 mL NS or D5W, infuse over 15-30 min<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IM:</strong> Deep IM injection, rotate sites<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Oral:</strong> 10 mg tablets, typically started after 2 days of parenteral therapy
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nausea, dyspepsia, abdominal pain (less than opioids)<br>
        ‚Ä¢ Headache, dizziness, drowsiness<br>
        ‚Ä¢ Injection site pain (IM route)<br>
        ‚Ä¢ Fluid retention, edema<br>
        ‚Ä¢ Hypertension<br>
        ‚Ä¢ Pruritus, rash
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ GI bleeding/perforation (1-2% with short-term use)<br>
        ‚Ä¢ Acute kidney injury (especially in volume-depleted, elderly, CKD)<br>
        ‚Ä¢ Cardiovascular events (MI, stroke) - risk increases with duration<br>
        ‚Ä¢ Anaphylactoid reactions (asthma exacerbation in aspirin-sensitive)<br>
        ‚Ä¢ Platelet dysfunction (increased bleeding time)<br>
        ‚Ä¢ Hepatotoxicity (rare)<br>
        ‚Ä¢ Aseptic meningitis (rare, in SLE patients)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Anticoagulants/antiplatelets:</strong> Increased bleeding risk (warfarin, heparin, clopidogrel)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">ACE inhibitors/ARBs:</strong> Reduced antihypertensive effect, renal impairment risk<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Diuretics:</strong> Reduced diuretic effect, renal impairment risk<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Lithium:</strong> Increased lithium levels (decreased renal clearance)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Methotrexate:</strong> Increased methotrexate toxicity<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Other NSAIDs:</strong> Additive toxicity - avoid concurrent use<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">SSRIs/SNRIs:</strong> Increased bleeding risk
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="anti-inflammatory-orange">"5 DAY RULE":</strong> Maximum duration 5 days - no exceptions!<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Opioid-sparing:</strong> Reduces opioid requirements by 30-50% when used with opioids<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Renal colic gold standard:</strong> More effective than opioids for ureteric stone pain<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">IV vs IM:</strong> IV preferred - faster onset, less painful, same efficacy<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Elderly/renal risk:</strong> Check creatinine before use, avoid if CrCl <30 mL/min<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">GI protection:</strong> Consider PPI if GI risk factors, but NO evidence for short-term use<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Asthma warning:</strong> Contraindicated in aspirin-sensitive asthma (cross-reactivity 10%)<br>
        ‚Ä¢ <strong class="anti-inflammatory-orange">Pregnancy:</strong> Category C (1st/2nd trimester), Category D (3rd trimester - ductus closure)
    </div>
</div>

<!-- CHAPTER 7: DRUG 6 - TETANUS IMMUNIZATION -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Tetanus Immunization</h2>

<div class="drug-template">
    <h4>TETANUS TOXOID & IMMUNOGLOBULIN - WOUND PROPHYLAXIS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Vaccine (toxoid) and passive immunization (immunoglobulin)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ <strong>Tetanus toxoid (TT/Td/Tdap):</strong> Inactivated toxin stimulates active immunity<br>
        ‚Ä¢ <strong>Tetanus immunoglobulin (TIG):</strong> Pre-formed antibodies provide immediate passive immunity<br>
        ‚Ä¢ Neutralizes circulating tetanus toxin before it binds to neurons<br>
        ‚Ä¢ Does NOT reverse bound toxin (once bound, only supportive care)<br>
        ‚Ä¢ Tetanus toxoid provides long-term protection (10 years booster)<br>
        ‚Ä¢ TIG provides immediate but temporary protection (weeks)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong>Tetanus toxoid:</strong> Primary immunization, booster every 10 years, wound prophylaxis<br>
        ‚Ä¢ <strong>Tetanus immunoglobulin:</strong> Passive immunization for high-risk wounds in inadequately immunized<br>
        ‚Ä¢ <strong>Wound management:</strong> Based on wound type and vaccination history<br>
        ‚Ä¢ <strong>Neonatal tetanus prevention:</strong> Maternal immunization during pregnancy<br>
        ‚Ä¢ <strong>Tetanus treatment:</strong> TIG as part of management (doesn't reverse symptoms)<br>
        ‚Ä¢ <strong>Post-exposure prophylaxis:</strong> For contaminated wounds in unvaccinated/unknown status
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ <strong>Absolute:</strong> Severe allergic reaction to previous dose<br>
        ‚Ä¢ <strong>Toxoid contraindications:</strong> Encephalopathy within 7 days of previous dose<br>
        ‚Ä¢ <strong>Precautions:</strong> Moderate/severe acute illness (delay until recovered)<br>
        ‚Ä¢ <strong>Guillain-Barr√© syndrome:</strong> Within 6 weeks of previous tetanus vaccine<br>
        ‚Ä¢ <strong>Immunoglobulin precautions:</strong> IgA deficiency (risk of anaphylaxis)<br>
        ‚Ä¢ <strong>Live vaccines:</strong> MMR/varicella should be given same day or separated by 4 weeks
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="immunization-teal">Tetanus toxoid (Td/Tdap):</strong> 0.5 mL IM single dose<br>
        ‚Ä¢ <strong class="immunization-teal">Tetanus immunoglobulin (TIG):</strong> 250-500 units IM single dose<br>
        ‚Ä¢ <strong class="immunization-teal">Wound management:</strong> Follow CDC algorithm (clean vs dirty wound, vaccination history)<br>
        ‚Ä¢ <strong class="immunization-teal">Primary series:</strong> 3 doses: 0, 1-2 months, 6-12 months<br>
        ‚Ä¢ <strong class="immunization-teal">Booster:</strong> Every 10 years (Td) or once as adult with Tdap, then Td<br>
        ‚Ä¢ <strong class="immunization-teal">Tetanus treatment:</strong> 3000-6000 units IM (part in wound edges)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="immunization-teal">DTaP (children <7 years):</strong> 0.5 mL IM at 2, 4, 6, 15-18 months, 4-6 years<br>
        ‚Ä¢ <strong class="immunization-teal">Tdap (‚â•7 years):</strong> 0.5 mL IM single dose (booster at 11-12 years)<br>
        ‚Ä¢ <strong class="immunization-teal">TIG:</strong> 4 units/kg IM (max 250 units)<br>
        ‚Ä¢ <strong class="immunization-teal">Neonates:</strong> Maternal immunization during pregnancy protects infant<br>
        ‚Ä¢ <strong class="immunization-teal">Primary series:</strong> Complete if unknown/incomplete status
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="immunization-teal">Routes:</strong> IM only (deltoid or vastus lateralis)<br>
        ‚Ä¢ <strong class="immunization-teal">Toxoid preparation:</strong> 0.5 mL prefilled syringe or vial<br>
        ‚Ä¢ <strong class="immunization-teal">TIG preparation:</strong> 250 units/mL vial<br>
        ‚Ä¢ <strong class="immunization-teal">Administration site:</strong> Different limbs for TIG and toxoid if both needed<br>
        ‚Ä¢ <strong class="immunization-teal">Needle size:</strong> 22-25 gauge, 1-1.5 inch for deltoid (based on size)<br>
        ‚Ä¢ <strong class="immunization-teal">Storage:</strong> Refrigerate (2-8¬∞C), do not freeze
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Injection site: Pain, redness, swelling (80% of recipients)<br>
        ‚Ä¢ Fever, malaise, headache (10-15%)<br>
        ‚Ä¢ Arthralgia, myalgia<br>
        ‚Ä¢ Nausea, vomiting, diarrhea<br>
        ‚Ä¢ Lymphadenopathy (regional)<br>
        ‚Ä¢ Mild allergic reactions (urticaria)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylaxis (rare: 1 in 1,000,000 doses)<br>
        ‚Ä¢ Brachial neuritis (rare)<br>
        ‚Ä¢ Guillain-Barr√© syndrome (rare association)<br>
        ‚Ä¢ Arthus reaction (severe local reaction in over-immunized)<br>
        ‚Ä¢ Syncope (especially adolescents)<br>
        ‚Ä¢ Extensive limb swelling (more common with boosters)<br>
        ‚Ä¢ Encephalopathy (extremely rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="immunization-teal">Immunosuppressants:</strong> Reduced immune response (chemotherapy, steroids, biologics)<br>
        ‚Ä¢ <strong class="immunization-teal">Other vaccines:</strong> Can be given simultaneously at different sites<br>
        ‚Ä¢ <strong class="immunization-teal">Blood products/immunoglobulins:</strong> May interfere with live vaccines (not tetanus)<br>
        ‚Ä¢ <strong class="immunization-teal">Warfarin:</strong> Increased bleeding risk at injection site (check INR)<br>
        ‚Ä¢ <strong class="immunization-teal">Aspirin/NSAIDs:</strong> Not contraindicated but may mask fever
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="immunization-teal">"Dirty wound + unknown vaccine = TIG + Toxoid"</strong><br>
        ‚Ä¢ <strong class="immunization-teal">Tdap vs Td:</strong> Tdap has pertussis component - give once as adult, then Td boosters<br>
        ‚Ä¢ <strong class="immunization-teal">Wound classification:</strong> Clean minor vs contaminated/tetanus-prone wounds<br>
        ‚Ä¢ <strong class="immunization-teal">History unknown/3 doses:</strong> Treat as unimmunized (give toxoid ¬± TIG)<br>
        ‚Ä¢ <strong class="immunization-teal">Last dose <5 years:</strong> No toxoid needed for clean minor wounds<br>
        ‚Ä¢ <strong class="immunization-teal">Last dose >10 years:</strong> Booster needed for any wound<br>
        ‚Ä¢ <strong class="immunization-teal">HIV/immunocompromised:</strong> Give TIG for any wound regardless of vaccine history<br>
        ‚Ä¢ <strong class="immunization-teal">Cost-effectiveness:</strong> $30 for TIG vs $3 million for tetanus treatment
    </div>
</div>

<div class="tetanus-box">
    <strong>üíâ TETANUS PROPHYLAXIS DECISION GUIDE:</strong><br>
    <br>
    <strong>CLEAN MINOR WOUND:</strong><br>
    ‚Ä¢ Unknown/‚â§3 doses: Give Td/Tdap<br>
    ‚Ä¢ Last dose ‚â•10 years: Give Td/Tdap<br>
    ‚Ä¢ Last dose <10 years: No vaccine needed<br>
    <br>
    <strong>CONTAMINATED/TETANUS-PRONE WOUND:</strong><br>
    ‚Ä¢ Unknown/‚â§3 doses: Give Td/Tdap + TIG<br>
    ‚Ä¢ Last dose ‚â•5 years: Give Td/Tdap<br>
    ‚Ä¢ Last dose <5 years: No vaccine needed<br>
    ‚Ä¢ NEVER give TIG if >24 hours post-injury (still give but less effective)
</div>

<!-- CHAPTER 8: TRAUMA ANALGESIA STRATEGY -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Trauma Analgesia Strategy</h2>

<div class="analgesia-box">
    <h3>8.1 Analgesia Ladder for Trauma & Surgical Pain</h3>
    
    <strong>MILD PAIN (1-3/10):</strong><br>
    ‚Ä¢ <strong class="analgesia-green">Paracetamol:</strong> 1g IV/PO q6h (max 4g/day)<br>
    ‚Ä¢ <strong class="analgesia-green">NSAIDs:</strong> Ibuprofen 400-800mg PO q6-8h (if no contraindications)<br>
    <br>
    <strong>MODERATE PAIN (4-6/10):</strong><br>
    ‚Ä¢ <strong class="analgesia-green">Paracetamol + NSAID combination</strong><br>
    ‚Ä¢ <strong class="analgesia-green">Weak opioids:</strong> Codeine 30-60mg PO q4-6h, Tramadol 50-100mg PO q6h<br>
    ‚Ä¢ <strong class="analgesia-green">Ketorolac:</strong> 15-30mg IV/IM q6h (max 5 days)<br>
    <br>
    <strong>MODERATE-SEVERE PAIN (6-8/10):</strong><br>
    ‚Ä¢ <strong class="analgesia-green">Strong opioids:</strong> Morphine 2-5mg IV q5-15min titrated<br>
    ‚Ä¢ <strong class="analgesia-green">Fentanyl:</strong> 25-100mcg IV q5-10min titrated<br>
    ‚Ä¢ <strong class="analgesia-green">Multimodal:</strong> Opioid + paracetamol + ketorolac (if no contraindications)<br>
    <br>
    <strong>SEVERE PAIN (9-10/10):</strong><br>
    ‚Ä¢ <strong class="analgesia-green">IV opioids titrated to effect</strong> with monitoring<br>
    ‚Ä¢ <strong class="analgesia-green">Consider regional anesthesia</strong> (nerve blocks, epidural)<br>
    ‚Ä¢ <strong class="analgesia-green">PCA (patient-controlled analgesia)</strong><br>
    ‚Ä¢ <strong class="analgesia-green">Ketamine</strong> (adjunct or primary for opioid-tolerant)<br>
</div>

<h3>8.2 Special Trauma Scenarios</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 25%;">Scenario</th>
            <th>Preferred Analgesic</th>
            <th>Alternative</th>
            <th>Avoid/Use with Caution</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Head injury + pain</strong></td>
            <td>Fentanyl (minimal hemodynamic effects)</td>
            <td>Paracetamol, short-acting opioids</td>
            <td>Morphine (respiratory depression ‚Üí increased ICP)</td>
        </tr>
        <tr>
            <td><strong>Hemorrhagic shock + pain</strong></td>
            <td>Fentanyl (titrated small doses)</td>
            <td>Ketamine (analgesic with pressor effects)</td>
            <td>Morphine (hypotension), NSAIDs (renal risk)</td>
        </tr>
        <tr>
            <td><strong>Multiple rib fractures</strong></td>
            <td>Epidural analgesia (gold standard)</td>
            <td>Paravertebral block, multimodal opioids</td>
            <td>High-dose opioids alone (respiratory depression)</td>
        </tr>
        <tr>
            <td><strong>Burn pain</strong></td>
            <td>IV opioids (morphine/fentanyl) + ketamine</td>
            <td>Gabapentinoids for neuropathic component</td>
            <td>IM injections (unreliable absorption)</td>
        </tr>
        <tr>
            <td><strong>Renal colic</strong></td>
            <td>Ketorolac 30mg IV (first line)</td>
            <td>Opioids (morphine/fentanyl) if NSAID contraindicated</td>
            <td>High fluid loads (no proven benefit, may increase pain)</td>
        </tr>
        <tr>
            <td><strong>Acute abdominal pain (undifferentiated)</strong></td>
            <td>Morphine/fentanyl titrated (safe, doesn't mask findings)</td>
            <td>Paracetamol</td>
            <td>NSAIDs (may worsen some conditions), antispasmodics</td>
        </tr>
    </tbody>
</table>

<!-- CHAPTER 9: SURGICAL EMERGENCIES PHARMACOLOGY -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Surgical Emergencies Pharmacology</h2>

<div class="trauma-box">
    <h3>9.1 Common Surgical Emergencies & Drug Management</h3>
    
    <strong>ü©∫ ACUTE ABDOMINAL PAIN (UNDIFFERENTIATED):</strong><br>
    ‚Ä¢ <strong>Analgesia:</strong> Opioids safe (morphine 2-5mg IV q5-15min)<br>
    ‚Ä¢ <strong>Antiemetics:</strong> Ondansetron 4-8mg IV, Metoclopramide 10mg IV<br>
    ‚Ä¢ <strong>Fluids:</strong> Resuscitation if septic/hypovolemic<br>
    ‚Ä¢ <strong>Antibiotics:</strong> If signs of infection/peritonitis<br>
    <br>
    <strong>üî™ TRAUMA LAPAROTOMY PREPARATION:</strong><br>
    ‚Ä¢ <strong>Antibiotics:</strong> Cefazolin 2g IV (add metronidazole if bowel injury)<br>
    ‚Ä¢ <strong>TXA:</strong> 1g IV load if within 3h of injury, 1g over 8h<br>
    ‚Ä¢ <strong>Blood products:</strong> Type & cross, consider MTP activation<br>
    ‚Ä¢ <strong>Analgesia:</strong> Fentanyl 50-100mcg IV boluses<br>
    <br>
    <strong>ü¶¥ OPEN FRACTURES:</strong><br>
    ‚Ä¢ <strong>Antibiotics:</strong> Cefazolin 2g IV (add gentamicin for Grade III)<br>
    ‚Ä¢ <strong>Tetanus:</strong> Per wound prophylaxis guidelines<br>
    ‚Ä¢ <strong>Analgesia:</strong> Multimodal (opioid + ketorolac + regional block)<br>
    ‚Ä¢ <strong>Timing:</strong> OR within 6 hours (golden period)<br>
    <br>
    <strong>üî• MAJOR BURNS:</strong><br>
    ‚Ä¢ <strong>Fluids:</strong> Parkland formula: 4mL √ó kg √ó %TBSA in first 24h<br>
    ‚Ä¢ <strong>Analgesia:</strong> IV opioids (morphine 0.1mg/kg), consider ketamine<br>
    ‚Ä¢ <strong>Tetanus:</strong> Update if >5 years since last dose<br>
    ‚Ä¢ <strong>Antibiotics:</strong> Not prophylactically, only for proven infection
</div>

<h3>9.2 Peri-operative Medication Management</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Medication Class</th>
            <th>Pre-operative Management</th>
            <th>Intra-operative Considerations</th>
            <th>Post-operative Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Anticoagulants (Warfarin)</strong></td>
            <td>Hold 5 days, check INR, consider bridging</td>
            <td>Reverse if emergent (PCC + Vitamin K)</td>
            <td>Restart when bleeding risk low (often 24-48h)</td>
        </tr>
        <tr>
            <td><strong>DOACs (Apixaban, Rivaroxaban)</strong></td>
            <td>Hold 2-3 days (CrCl dependent)</td>
            <td>Idarucizumab (dabigatran) or Andexanet (Xa inhibitors) if bleeding</td>
            <td>Restart 24-72h post-op depending on bleed risk</td>
        </tr>
        <tr>
            <td><strong>Antiplatelets (Aspirin, Clopidogrel)</strong></td>
            <td>Continue aspirin, hold clopidogrel 5-7 days if possible</td>
            <td>Increased bleeding risk, may need platelets</td>
            <td>Restart clopidogrel when safe (often 24h)</td>
        </tr>
        <tr>
            <td><strong>Beta-blockers</strong></td>
            <td>Continue (prevents peri-op MI)</td>
            <td>May need intra-operative titration</td>
            <td>Continue, watch for bradycardia</td>
        </tr>
        <tr>
            <td><strong>ACE inhibitors/ARBs</strong></td>
            <td>Hold morning of surgery (hypotension risk)</td>
            <td>May need vasopressors for hypotension</td>
            <td>Restart when BP stable, eating/drinking</td>
        </tr>
        <tr>
            <td><strong>Insulin</strong></td>
            <td>Long-acting: Give 50-80% dose, short-acting: hold</td>
            <td>Sliding scale, target glucose 6-10 mmol/L</td>
            <td>Resume usual regimen when eating</td>
        </tr>
    </tbody>
</table>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Trauma Drug Dosing Quick Guide</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Adult Dose</th>
            <th>Pediatric Dose</th>
            <th>Onset</th>
            <th>Duration</th>
            <th>Special Considerations</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Tranexamic Acid</strong></td>
            <td>1g IV over 10min, then 1g over 8h</td>
            <td>15 mg/kg load, then 2 mg/kg/hr</td>
            <td>Minutes</td>
            <td>8h infusion</td>
            <td>Within 3h of injury maximum benefit</td>
        </tr>
        <tr>
            <td><strong>Vitamin K (IV)</strong></td>
            <td>5-10 mg IV over 20-60min</td>
            <td>0.025-0.1 mg/kg IV</td>
            <td>1-2h</td>
            <td>2-5 days</td>
            <td>NEVER IV push, dilute and infuse slowly</td>
        </tr>
        <tr>
            <td><strong>Morphine IV</strong></td>
            <td>2-5 mg q5-15min titrated</td>
            <td>0.05-0.1 mg/kg q2-4h</td>
            <td>5-10min</td>
            <td>3-4h</td>
            <td>Histamine release ‚Üí itching, hypotension</td>
        </tr>
        <tr>
            <td><strong>Fentanyl IV</strong></td>
            <td>25-100 mcg q5-10min</td>
            <td>0.5-1 mcg/kg q30-60min</td>
            <td>1-2min</td>
            <td>30-60min</td>
            <td>100x morphine potency, chest wall rigidity risk</td>
        </tr>
        <tr>
            <td><strong>Ketorolac IV</strong></td>
            <td>15-30 mg q6h (max 5 days)</td>
            <td>0.5 mg/kg q6h</td>
            <td>30min</td>
            <td>6-8h</td>
            <td>MAX 5 DAYS total, renal/GI risk</td>
        </tr>
        <tr>
            <td><strong>Tetanus Toxoid</strong></td>
            <td>0.5 mL IM single dose</td>
            <td>0.5 mL IM (DTaP/Tdap)</td>
            <td>Days (immunity)</td>
            <td>10 years</td>
            <td>Follow wound prophylaxis guidelines</td>
        </tr>
    </tbody>
</table>

<h3>Tetanus Prophylaxis Algorithm</h3>

<div class="clinical-pearl">
    <strong>üìã TETANUS WOUND MANAGEMENT (CDC GUIDELINES):</strong><br>
    <br>
    <strong>STEP 1: Classify wound</strong><br>
    ‚Ä¢ <em>Clean, minor:</em> Little contamination, >6h old<br>
    ‚Ä¢ <em>Tetanus-prone:</em> >6h old, >1cm deep, puncture, avulsion, crush, burn, frostbite, contaminated<br>
    <br>
    <strong>STEP 2: Check vaccine history</strong><br>
    ‚Ä¢ Unknown or <3 doses: Consider unvaccinated<br>
    ‚Ä¢ 3 doses: Consider vaccinated but check timing<br>
    <br>
    <strong>STEP 3: Decide on Tetanus Toxoid (Td/Tdap)</strong><br>
    ‚Ä¢ Clean minor: Give if >10 years since last dose<br>
    ‚Ä¢ Tetanus-prone: Give if >5 years since last dose<br>
    ‚Ä¢ Unknown/<3 doses: Always give<br>
    <br>
    <strong>STEP 4: Decide on Tetanus Immunoglobulin (TIG)</strong><br>
    ‚Ä¢ Clean minor: Never needed<br>
    ‚Ä¢ Tetanus-prone: Give if unknown/<3 doses or if HIV/immunocompromised<br>
    ‚Ä¢ Give TIG and toxoid in different limbs with different syringes
</div>

<h3>Massive Hemorrhage Protocol (MHP) Checklist</h3>
<ol>
    <li><strong>Activate MHP</strong> early (>4 units predicted in 1h or ongoing shock)</li>
    <li><strong>TXA 1g IV</strong> if within 3h of injury</li>
    <li><strong>Blood products</strong> in 1:1:1 ratio (PRBC:FFP:platelets)</li>
    <li><strong>Consider cryoprecipitate/fibrinogen</strong> if fibrinogen <1.5 g/L</li>
    <li><strong>Calcium chloride</strong> 1g IV if massive transfusion (citrate toxicity)</li>
    <li><strong>Avoid excessive crystalloid</strong> (<2L initially)</li>
    <li><strong>Permissive hypotension</strong> (SBP 80-90 mmHg) if no head injury</li>
    <li><strong>Damage control surgery</strong> if ongoing bleed</li>
    <li><strong>Rewarm patient</strong> (avoid hypothermia)</li>
    <li><strong>Monitor</strong> labs q30-60min (Hb, INR, fibrinogen, Ca¬≤‚Å∫, pH)</li>
</ol>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 7 of 10
</div>

</body>
</html>